Pavion Blue Capital LLC has increased its investment in Pfizer Inc. (NYSE: PFE) by 8.8% during the second quarter of 2023, according to HoldingsChannel. The fund now owns a total of 9,787 shares, following the acquisition of an additional 788 shares. As of the end of the most recent quarter, Pavion Blue Capital’s stake in Pfizer was valued at approximately $237,000.
Other institutional investors have also made adjustments to their holdings in Pfizer. Capital Advisory Group Advisory Services LLC raised its stake by 2.9%, now owning 13,542 shares valued at $328,000. Citizens National Bank Trust Department increased its holdings by 0.9%, bringing its total to 46,103 shares worth $1,118,000. Trust Co of the South added to its position with a 1.5% increase, now holding 29,386 shares valued at $712,000. Additionally, Charter Oak Capital Management LLC raised its stake by 4.3%, owning 10,663 shares worth $258,000, while Ballentine Partners LLC grew its holdings by 0.5%, now owning 93,228 shares valued at $2.26 million. Overall, hedge funds and institutional investors collectively own 68.36% of Pfizer’s stock.
Wall Street Analysts Update Ratings
Several research analysts have recently provided updates regarding Pfizer’s stock. On October 10, 2023, Morgan Stanley lowered its price target for Pfizer from $33.00 to $32.00 while maintaining an “equal weight” rating. Weiss Ratings restated a “hold (c-)” rating, while UBS Group reaffirmed a “neutral” rating with a target price of $28.00. Wall Street Zen downgraded Pfizer from a “buy” to a “hold” rating, and Citigroup increased its target from $25.00 to $26.00 with a “neutral” rating.
Currently, two analysts have assigned Pfizer a Strong Buy rating, four have given it a Buy rating, eleven have issued a Hold rating, and one has assigned a Sell rating. Data from MarketBeat.com indicates that the average rating for Pfizer is “Hold,” with an average target price of $28.13.
Current Stock Performance and Financials
On October 10, 2023, Pfizer shares opened at $24.76. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16, and a quick ratio of 0.85. Over the past year, Pfizer’s stock has fluctuated between a low of $20.92 and a high of $29.17. The stock’s 50-day moving average stands at $24.86, while the 200-day moving average is $24.21. Pfizer holds a market capitalization of $140.75 billion, with a price-to-earnings ratio of 13.17 and a PEG ratio of 0.82.
In its latest earnings report, issued on August 5, 2023, Pfizer reported earnings per share (EPS) of $0.78, exceeding the consensus estimate of $0.58 by $0.20. The company achieved a net margin of 16.84% and a return on equity of 21.42%, with quarterly revenue of $14.65 billion, surpassing analysts’ expectations of $13.43 billion. This marked a year-over-year revenue increase of 10.3%.
Looking ahead, Pfizer has set its FY 2025 guidance at an EPS range of $2.90 to $3.10. Analysts project the company will report an EPS of $2.95 for the current fiscal year.
Pfizer also recently announced a quarterly dividend payment of $0.43 per share, scheduled for distribution on December 1, 2023, to shareholders of record as of November 7, 2023. This translates to an annualized dividend of $1.72 and represents a yield of 6.9%, with the ex-dividend date set for November 7, 2023. Currently, Pfizer’s dividend payout ratio stands at 91.49%.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells various pharmaceutical products across the United States, Europe, and other regions. The company’s portfolio includes medicines and vaccines in therapeutic areas such as cardiovascular health, migraine treatment, and women’s health, as well as products for infectious diseases, including COVID-19 prevention and treatment. Noteworthy brands include Eliquis, Comirnaty, and Paxlovid.
For the latest updates on Pfizer and its stakeholders, investors can visit HoldingsChannel.com for detailed insights into recent filings and insider trades.
